多模式镇痛用于单孔胸腔镜肺切除术后快速恢复外科的研究

注册号:

Registration number:

ChiCTR-IPR-15007327 

最近更新日期:

Date of Last Refreshed on:

2015-11-04 10:40:33 

注册时间:

Date of Registration:

2015-10-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

多模式镇痛用于单孔胸腔镜肺切除术后快速恢复外科的研究

Public title:

Randomized clinical trial on multimodal analgesia in fast-track surgery after single-incision video-assisted thoracoscopic lobectomy and segmentectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

多模式镇痛用于单孔胸腔镜肺切除术后快速恢复外科的研究

Scientific title:

Randomized clinical trial on multimodal analgesia in fast-track surgery after single-incision video-assisted thoracoscopic lobectomy and segmentectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

查鹏 

研究负责人:

查鹏 

Applicant:

Peng Cha 

Study leader:

Peng Cha 

申请注册联系人电话:

Applicant telephone:

+86 18618373695

研究负责人电话:

Study leader's
telephone:

+86 18618373695

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

bmyouyu@sina.com

研究负责人电子邮件:

Study leader's E-mail:

bmyouyu@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区阜成路6#

研究负责人通讯地址:

北京市海淀区阜成路6#

Applicant address:

6 Fucheng road, Haidian District, Beijing, China.

Study leader's address:

6 Fucheng road, Haidian District, Beijing, China.

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

海军总医院

Applicant's institution:

PLA Navy General Hospital

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

海军总医院

Primary sponsor:

PLA Navy General Hospital

研究实施负责(组长)单位地址:

北京市海淀区阜成路6#

Primary sponsor's address:

6 Fucheng road, Haidian District, Beijing, China.

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

海军总医院

具体地址:

北京市海淀区阜成路6#

Institution
hospital:

PLA Navy General Hospital

Address:

6 Fucheng road, Haidian District, Beijing, China.

经费或物资来源:

海军总医院胸外科

Source(s) of funding:

Department of thoracic surgery, PLA Navy General Hospital

研究疾病:

肺癌  

Target disease:

lung cancer

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探索将多模式镇痛用于单孔胸腔镜肺叶切除术,研究其对患者术后早期呼吸功能和机体活动恢复以及免疫功能的影响,进而形成单孔胸腔镜肺叶切除术后快速恢复外科模式,促进患者术后的快速康复,提高患者术后生活质量,改善患者长期预后。  

Objectives of Study:

Multimodal anesthesia will be applied to single-incision thoracoscopic lobectomy and segmentectomyand its influence on postoperative recovery of pulmonary functionlimb function and immunologic function will be assessed. Then model of fast recovery surgery after single-incision thoracoscopic lobectomy and segmentectomy will be constituted to promote the postoperative recovery,and improve the postoperative quality of life and long-term prognosis of patients.

药物成份或治疗方案详述:

N-[[4-(5-甲基-3-苯基-4-异恶唑基)苯基]磺酰基]丙酰胺盐 

Description for medicine or protocol of treatment in detail:

N-[[4-(5-甲基-3-苯基-4-异恶唑基)苯基]磺酰基]丙酰胺盐 

纳入标准:

Inclusion criteria

排除标准:

1)美国麻醉医师协会分级≥Ⅲ级;
2)合并冠心病、心肌梗死或心律失常等心脏病;
3)脑血管疾病;
4)消化道溃疡等胃肠疾病;
5)肝脏或肾脏疾病;
6)凝血障碍;
7)NSAIDS药物过敏;
8)患者拒绝。

Exclusion criteria:

1. ASA grade>=III;
2. cardiac disease such as coronary artery disease,myocardial infarction and arrhythmia;
3. cerebral vessel disease;
4. gastrointestinal disease such as peptic ulcer;
5. hepatic or renal disease;
6. coagulation disorders;
7. allergy to NSAIDS;
8. patient refusal.

研究实施时间:

Study execute time:

From 2016-01-01 00:00:00 To 2017-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2016-01-01 00:00:00 To 2017-12-31 00:00:00

干预措施:

Interventions:

组别:

多模式镇痛组

样本量:

60

Group:

Parecoxib group

Sample size:

干预措施:

帕瑞昔布钠+肋间神经阻滞

干预措施代码:

Intervention:

Parecoxib+intercostal nerve block

Intervention code:

组别:

患者自控镇痛泵组

样本量:

60

Group:

Patient-controlled analgesia group

Sample size:

干预措施:

患者自控镇痛泵

干预措施代码:

Intervention:

Patient-controlled analgesia

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

海军总医院 

单位级别:

三级甲等 

Institution
hospital:

PLA navy general hospital

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

临床恢复时间

指标类型:

主要指标

Outcome:

medical recovery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛指数

指标类型:

主要指标

Outcome:

Pain scales

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后住院天数、总住院天数及住院费用

指标类型:

次要指标

Outcome:

Postoperative stay,duration and cost of hospitalization

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

围手术期并发症

指标类型:

副作用指标

Outcome:

postoperative morbidity

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肢体活动功能

指标类型:

次要指标

Outcome:

limb function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

镇痛药物总量

指标类型:

次要指标

Outcome:

Opioids or other analgesic drugs consumption

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

全身炎症反应综合征

指标类型:

副作用指标

Outcome:

systemic inflammatory response syndrome

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胸腔引流时间及总量

指标类型:

次要指标

Outcome:

the time of chest drainage and the total amount of chest drainage

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者根据电脑产生的随机数字表产生

Randomization Procedure (please state who generates the random number sequence and by what method):

Study leader generates the random number sequence by computer generated random number

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

海军总医院

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

PLA navy general hospital

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

海军总医院

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

PLA navy general hospital

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2015-11-04 10:40:34